Quarterly report pursuant to Section 13 or 15(d)

Nature of Business and Significant Accounting Policies (Details Narrative)

v3.24.3
Nature of Business and Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
May 15, 2024
Feb. 21, 2019
Sep. 30, 2024
Sep. 30, 2023
Mar. 31, 2022
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Loss on deconsolidation of foreign subsidiaries     $ 22,359   $ 242,631 $ 1,564,823
Purchase price of license fair value           75,000  
FDIC insured amount     250,000     250,000    
Cash uninsured amount     $ 0     $ 0    
Petalo Pharmaceutical, S.A.S [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Purchase price of license fair value $ 75,000              
Merger Agreement [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Share based payment award shares purchased   825,000            
Share price   $ 0.50            
Merger Agreement [Member] | OWP Ventures, Inc. [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Business acquisition, equity interest issued or issuable, number of shares   39,475,398            
Share based payment award shares purchased   825,000            
Share price   $ 0.50            
Proceeds from convertible debt   $ 300,000            
Conversion price   $ 0.424            
Common stock shares cancelled   875,000            
Payments for custom clearance         $ 1,400,000